$PMCB For the time being, Pharmacyte is comfortably financed through a $50 million at-the-market facility. But with the prospect of large trials looming down the road, the company also is assessing the interest of big pharmas, and many have signed nondisclosure agreements. “We’ve been approached by a number of people who want to get involved,” Waggoner said. “They’ve recognized that our treatment is very different from any approach that’s out there.”
READ BETWEEN THE LINE AND DECIDE FOR YOURSELF WHEN INVESTED INTO PMCB
Go $PMCB